AstraZeneca Starts Artificial Intelligence Collaboration to Accelerate Drug Discovery

AstraZenecaAstraZeneca and BenevolentAI began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treatments for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF).

Scientists from the two organisations will work side-by-side to combine AstraZeneca's genomics, chemistry and clinical data with BenevolentAI's target identification platform and biomedical knowledge graph - a network of contextualised scientific data (genes, proteins, diseases and compounds) and the relationship between them.

Machine learning systematically analyses data to find connections between facts, and AI-based reasoning is used to extrapolate previously unknown connections. Together, the companies will interpret the results to understand the underlying mechanisms of these complex diseases and more quickly identify new potential drug targets.

Mene Pangalos, Executive Vice President and President BioPharmaceuticals R&D, said: "The vast amount of data available to research scientists is growing exponentially each year. By combining AstraZeneca's disease area expertise and large, diverse datasets with BenevolentAI’s leading AI and machine learning capabilities, we can unlock the potential of this wealth of data to improve our understanding of complex disease biology and identify new targets that could treat debilitating diseases."

Joanna Shields, Chief Executive Officer, BenevolentAI, said: "Millions of people today suffer from diseases that have no effective treatment. The future of drug discovery and development lies in bridging the gap between AI, data, and biology. We are thrilled to be joining forces with AstraZeneca to develop new insights and identify promising new treatments for chronic kidney disease and idiopathic pulmonary fibrosis."

CKD and IPF are complex diseases in which the underlying disease biology is poorly understood. This disease complexity requires the interrogation of vast, rich datasets.

BenevolentAI is a global AI leader focused on drug discovery. The company has developed the Benevolent Platform, an AI discovery platform which can be used by scientists to try to discover novel pathways and mechanisms important in the pathophysiology of disease.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Most Popular Now

Almirall Takes a Leap into Dermatology D…

Almirall, S.A. (ALM) has launched its first call for innovation to start-ups focused on dermatology digital health. This initiative is the first step in the creation of an accelerator programme...

The Bristol-Myers Squibb-Pfizer Alliance…

The Bristol-Myers Squibb-Pfizer Alliance and Fitbit announced at the TIME 100 Health Summit in New York that they are working together to help drive timely diagnosis of atrial fibrillation (AFib)...

Philips and Spencer Health Solutions Exp…

Building on their successful partnership providing medication adherence solutions to high-acuity patients in the U.S. Royal Philips (NYSE:PHG, AEX:PHIA), a global leader in health technology, and Spencer Health Solutions announced...

Using Artificial Intelligence to Predict…

Thyroid nodules are small lumps that form within the thyroid gland and are quite common in the general population, with a prevalence as high as 67%. The great majority of...

Bayer Launches LifeHub UK Focused on Art…

Bayer launched LifeHub UK to accelerate and optimize disease detection and data-driven drug discovery by developing artificial-intelligence-enabled imaging solutions. The new hub is the seventh pillar of Bayer's global network...

AI could Offer Warnings about Serious Si…

The more medications a patient takes, the greater the likelihood that interactions between those drugs could trigger negative side effects, including long-term organ damage and even death. Now, researchers at...

NHS Health Tech Team of the Year Named

A pioneering NHS trust has been recognised at the 2019 HTN Awards for its innovative work using InterSystems technology to help enhance care for hundreds of thousands of patients. North...

Philips and Klinikum Stuttgart Hospital …

Royal Philips (NYSE:PHG, AEX:PHIA), a global leader in health technology, and German Klinikum Stuttgart hospital, the largest provider in the region, announced they have signed a comprehensive 10-year innovation partnership...

Heartbeat Labs Hired Babylon Health's Ch…

The Berlin-based digital health platform Heartbeat Labs hired Chad Jennings as Chief Product Officer (CPO). Chad is a product and design leader with twenty years of experience at the intersection...

Combination of AI & Radiologists mor…

An artificial intelligence (AI) tool - trained on roughly a million screening mammography images - identified breast cancer with approximately 90 percent accuracy when combined with analysis by radiologists, a...

Abbott and Omada Health Partner to Offer…

Abbott (NYSE: ABT) and Omada Health announced today they are partnering to integrate Abbott's revolutionary FreeStyle Libre system, a continuous glucose monitoring (CGM) technology, with Omada Health's pioneering digital care...

First Entirely Digital Clinical Trial En…

As little as a daily ping on your phone can boost physical activity, researchers from the Stanford University School of Medicine and their collaborators report in a new study. The...